pharmaphorum

MAY 9, 2022

Mental health issues among teens and young adults have risen dramatically over the past decade. Jessica Lake, chief science officer at Limbix, tells us about SparkRx, a digital therapeutics app aimed to help treat adolescent depression. . SparkRx is designed to decrease depression in individuals aged 13 to 22 by providing a multi-week programme based on cognitive behavioural therapy (CBT) and behavioural activation protocols.

135

135

Outsourcing Pharma

MAY 9, 2022

The thin-film freezing specialist reports positive safety and pharmacokinetic data coming out of the Phase I trial of its niclosamide inhalation powder.

88

88

pharmaphorum

MAY 9, 2022

A study has shown that a mobile game can be used to gather symptom data from children undergoing treatment for cancer, and potentially might also be used to provide personalised management of their care. That is the conclusion of a small US study looking at the role of Color Me Healthy, a gaming app developed through a collaboration between children, game designers and clinical staff.

Chemotherapy 129

Chemotherapy 129

Outsourcing Pharma

MAY 9, 2022

Illumina has recently announced a 10-year-long strategic collaboration with Janssen Biotech, and a five-year partnership with Deerfield Management.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 9, 2022

Adding Nykode Therapeutics’ VB10.16 vaccine to treatment with Roche’s cancer immunotherapy Tecentriq resulted in disease control in two-thirds of patients with advanced cervical cancer. The combination of vaccine and checkpoint inhibitor had an overall response rate of 21% in the phase 2 VB C-02 trial involving 39 patients with HPV16-positive cervical cancer, including two complete responses and six partial responses with six months follow-up, said the Norwegian biotech.

Vaccines 64

Vaccines Immunization 64

Pharma Times

MAY 9, 2022

Link up between AbbVie and Cerebras Systems boosts AI platforms, while radically reducing energy consumption

42

42

Pharma Times

MAY 9, 2022

Vital patent for Evotenix is anticipated to enable a new generation of DNA synthesis platforms

43

43

pharmaphorum

MAY 9, 2022

Seagen’s chief executive Clay Siegall has taken leave of absence pending an investigation into an alleged domestic violence incident at his home. Siegall denies the allegations and has told the company he is in the midst of divorce proceedings, but in the meantime Seagen’s chief medical officer of four years – Roger Dansey – will take over as interim CEO.

52

52

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). J&J’s Janssen pharmaceuticals division said it will continue to work with the Danish biotech on vaccines targeting HIV and Ebola , but is prioritising its work in HBV on “alternative investigational vaccine platforms and therapeutics.” Janssen started working with Bavarian

Vaccines 52

Vaccines 52

pharmaphorum

MAY 9, 2022

Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed a phase 2 trial and will be terminated. The decision affects THR-687, a pan RGD integrin antagonist for the treatment of diabetic macular oedema (DME), and leaves Oxurion with a single clinical-stage candidate – plasma kallikrein (PKal) inhibitor THR-149 – which is in phase 2 for the same indication.

52

52

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA